CELLECT BIOTECH/S (APOP) Reaches New 12-Month Low at $3.00

Share on StockTwits

Shares of CELLECT BIOTECH/S (NASDAQ:APOP) hit a new 52-week low during mid-day trading on Thursday . The company traded as low as $3.00 and last traded at $3.22, with a volume of 243 shares traded. The stock had previously closed at $3.27.

Separately, HC Wainwright restated a “buy” rating and issued a $14.00 price target on shares of CELLECT BIOTECH/S in a research report on Wednesday, August 29th.

The stock has a market capitalization of $16.75 million, a PE ratio of -2.23 and a beta of 2.59.

CELLECT BIOTECH/S (NASDAQ:APOP) last issued its quarterly earnings results on Tuesday, November 13th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.01). On average, equities research analysts predict that CELLECT BIOTECH/S will post -0.98 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “CELLECT BIOTECH/S (APOP) Reaches New 12-Month Low at $3.00” was originally reported by Equities Focus and is owned by of Equities Focus. If you are reading this story on another website, it was illegally copied and republished in violation of US and international trademark & copyright legislation. The correct version of this story can be read at https://www.equitiesfocus.com/2018/12/08/cellect-biotech-s-apop-reaches-new-12-month-low-at-3-00.html.

CELLECT BIOTECH/S Company Profile (NASDAQ:APOP)

Cellect Biotechnology Ltd., a biotechnology company, focuses on developing technologies for the functional selection of stem cells in the field of regenerative medicine and stem cell therapies in Israel. It is developing the Apotainer selection kit, a shelf stem cell selection kit, based on its Powered by Cellect technology platform for allogeneic hematopoietic stem cell transplantation procedures for patients suffering from hematological malignancies.

Featured Story: Relative Strength Index

Receive News & Ratings for CELLECT BIOTECH/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CELLECT BIOTECH/S and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply